Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 14/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640950 | 1.00 | ACSS2 (0.65) | ACSS2GLAALOX15MAPTTNF | |
| SCHEMBL23843491 | 0.91 | ACSS2 (0.79) | ACSS2GLAALOX15MAPTALDH1A1 | |
| SCHEMBL30640961 | 0.91 | ACSS2 (0.79) | ACSS2GLAALOX15MAPTALDH1A1 | |
| SCHEMBL23832307 | 0.90 | ACSS2 (0.64) | ACSS2GLAALOX15MAPTKMT2A | |
| SCHEMBL26046982 | 0.89 | ACSS2 (0.56) | ACSS2GLAALOX15MAPTKMT2A | |
| SCHEMBL23843515 | 0.85 | ACSS2 (0.56) | ACSS2GLAALOX15ALDH1A1CYP2C9 | |
| SCHEMBL30640954 | 0.85 | ACSS2 (0.56) | ACSS2GLAALOX15ALDH1A1CYP2C9 | |
| SCHEMBL26047003 | 0.82 | ACSS2 (0.54) | ACSS2GLAALOX15MAPTKMT2A | |
| SCHEMBL26046975 | 0.82 | ACSS2 (0.65) | ACSS2GLAALOX15ALDH1A1 | |
| SCHEMBL25367234 | 0.81 | ACSS2 (0.43) | ACSS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| WO-2021185789-A1 | CONDENSED PYRIDINE DERIVASTIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS | MERCK PATENT GMBH (DE) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | BRCA1, HRAS, PCNA | ACSS2 201/4885GLA 1335/4885ALOX15 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.